Daniel Rabinowitz, the Secretary and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), a company with a market capitalization of $22.7 billion and an impressive 158% return over the past year according to InvestingPro, recently executed significant stock transactions, according to a recent filing. On January 22, Rabinowitz sold 22,039 shares of Natera's common stock, generating approximately $3.64 million. The shares were sold at prices ranging from $164.9488 to $171.948 per share, with the stock currently trading near its 52-week high. InvestingPro subscribers have access to 12 additional key insights about Natera's valuation and performance metrics.
The transactions were part of a plan to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs). Rabinowitz also acquired 1,500 shares of common stock through the vesting of RSUs on January 20 and 21, at no cost, as indicated in the filing. Following these transactions, Rabinowitz holds 217,793 shares in the company, which maintains a GOOD overall financial health score according to InvestingPro analysis.
In other recent news, Natera Inc . expanded its patent infringement lawsuit against NeoGenomics (NASDAQ:NEO) over the RaDaR test, with the inclusion of an additional patent. The company also reported strong Q3 earnings, with a 64% year-over-year increase in revenue to $439.8 million. The company conducted 137,000 oncology tests, marking a 54% increase from the previous year. Amid these developments, TD Cowen, Baird, and Jefferies maintained favorable ratings on Natera's stock and raised their price targets.
Natera faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:GH) but plans to request the court to overturn the ruling. In other company news, Natera has amended an agreement with its Executive Chairman, Dr. Rabinowitz, to continue his role under certain conditions. These are the recent developments in Natera's business operations and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.